Loading...
Findings from the large, open-label, randomized REDUCE-AMI trial published earlier this year showed no benefit of beta-blockers for secondary prevention in patients who had undergone revascularization for acute myocardial infarction (MI) and had a left ventricular ejection fraction (LVEF) ≥50% (NEJM JW Cardiol Apr 8 2024 and N Engl J Med 2024; 390:1372). Now, results are available from another open-label, randomized trial examining beta-blocker interruption versus continuation post–acute MI (ABYSS; NCT03498066).
The trial included 3698 patients with an LVEF ≥40% who were receiving beta-blocker therapy after acute MI. None had a recent cardiovascular event or chronic heart failure. Beta-blocker interruption of at least 6 months after MI did n…